{"title":"人腔囊泡菌;是敌是友。","authors":"Gavin Guard","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p><i>Blastocystis hominis (B. hominis)</i> remains the most common parasite identified through stool examination. A clinician will undoubtedly encounter the presence of this parasite numerous times in their career. Thus, it is vital to know if this organism is a 'friend or foe', or in other words, whether it is a commensal or a pathogen. This will help clinicians decide whether to treat or not. This literature review discusses the best available evidence of the association of <i>B. hominis</i> and two diseases- irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Particularly, focus has been paid to the effect of antimicrobial therapy in improving disease activity/symptoms and concluding on the pathogenicity of <i>B. hominis</i> based on <i>in vitro</i>, observational studies, and randomized controlled trials. Most importantly, the review presents a concise set of recommendations for when and how to treat <i>B. hominis</i> in a patient presenting gastrointestinal ailments.</p>","PeriodicalId":13593,"journal":{"name":"Integrative medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552959/pdf/","citationCount":"0","resultStr":"{\"title\":\"Blastocystis hominis; Friend or Foe.\",\"authors\":\"Gavin Guard\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>Blastocystis hominis (B. hominis)</i> remains the most common parasite identified through stool examination. A clinician will undoubtedly encounter the presence of this parasite numerous times in their career. Thus, it is vital to know if this organism is a 'friend or foe', or in other words, whether it is a commensal or a pathogen. This will help clinicians decide whether to treat or not. This literature review discusses the best available evidence of the association of <i>B. hominis</i> and two diseases- irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Particularly, focus has been paid to the effect of antimicrobial therapy in improving disease activity/symptoms and concluding on the pathogenicity of <i>B. hominis</i> based on <i>in vitro</i>, observational studies, and randomized controlled trials. Most importantly, the review presents a concise set of recommendations for when and how to treat <i>B. hominis</i> in a patient presenting gastrointestinal ailments.</p>\",\"PeriodicalId\":13593,\"journal\":{\"name\":\"Integrative medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552959/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Integrative medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Blastocystis hominis (B. hominis) remains the most common parasite identified through stool examination. A clinician will undoubtedly encounter the presence of this parasite numerous times in their career. Thus, it is vital to know if this organism is a 'friend or foe', or in other words, whether it is a commensal or a pathogen. This will help clinicians decide whether to treat or not. This literature review discusses the best available evidence of the association of B. hominis and two diseases- irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Particularly, focus has been paid to the effect of antimicrobial therapy in improving disease activity/symptoms and concluding on the pathogenicity of B. hominis based on in vitro, observational studies, and randomized controlled trials. Most importantly, the review presents a concise set of recommendations for when and how to treat B. hominis in a patient presenting gastrointestinal ailments.